Anti-Leukotriene A4 hydrolase/LTA4H antibody

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

Leukotriene A4 hydrolase often called LTA4H is an enzyme that converts leukotriene A4 into leukotriene B4 an important mediator in inflammation. It has a molecular mass of approximately 69 kDa and functions as a zinc metalloprotease. Expression of LTA4H is widespread detected in various tissues including the lung liver and kidney. This enzyme plays an essential role in modulating inflammatory responses due to its ability to catalyze the transformation of leukotriene A4.

Biological function summary

Leukotriene A4 hydrolase (LTA4H) transforms leukotriene A4 an unstable epoxide into leukotriene B4 a potent chemoattractant. The enzyme does not function within a multi-protein complex but interacts with small molecules during leukotriene biosynthesis. Leukotriene B4 produced by LTA4H recruits neutrophils to sites of inflammation enhancing immune defense. While its primary function is promoting inflammation this activity also regulates the resolution phase by facilitating tissue repair and return to homeostasis.

Pathways

Leukotriene A4 hydrolase plays a role in the arachidonic acid cascade an important biological pathway for synthesizing eicosanoids. This pathway involves several steps where arachidonic acid releases from cell membrane phospholipids and converts to intermediate leukotriene A4 by 5-lipoxygenase. LTA4H then converts leukotriene A4 into leukotriene B4 which orchestrates inflammatory responses. LTA4H connects to proteins like 5-lipoxygenase which also acts within this cascade.

Associated diseases and disorders

Leukotriene A4 hydrolase associates with inflammatory diseases such as asthma and inflammatory bowel disease. In asthma the overproduction of leukotriene B4 can exacerbate airway inflammation and hyperresponsiveness. Here leukotrienes interact with receptors on effector cells which contributes to the pathology of asthma. Inflammatory bowel disease showcases a similar link where increased levels of leukotriene B4 potentiate intestinal inflammation. Effective management of these conditions may involve targeting leukotriene pathways specifically inhibiting the activity of LTA4H to ameliorate symptoms.